A Multicenter, Open-label, Dose Escalation, Phase I Study of LJM716 Administered Intravenously in Combination With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast Cancer or Gastric Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 04 Apr 2017
At a glance
- Drugs Elgemtumab (Primary) ; Trastuzumab (Primary)
- Indications Breast cancer; Gastric cancer
- Focus Adverse reactions
- Sponsors Novartis
- 07 Jun 2017 Biomarkers information updated
- 05 Mar 2016 Planned End Date changed from 1 Oct 2015 to 1 Dec 2016, as reported by ClinicalTrials.gov.
- 05 Mar 2016 Planned primary completion date changed from 1 Oct 2015 to 1 Dec 2016, as reported by ClinicalTrials.gov.